finasteride / Generic mfg. - LARVOL DELTA

ZBTB7B modulates the androgen receptor as an upstream regulator via colocalization and direct binding in LNCaP prostate cancer cells. (PubMed, Transl Cancer Res) - "Furthermore, AR inhibitor finasteride and AR activator dihydrotestosterone (DHT) did not affect ZBTB7B...Notably, N-terminal domain (NTD) of AR is requisite for binding with ZBTB7B in HEK293 cells, not AR-DNA-binding domain (DBD) or AR-ligand-binding domain (LBD) in HEK293 cells. Overall, these findings provide a novel insight that ZBTB7B promotes prostate cancer progression as a potent oncogene via colocalization and binding with AR."

Journal • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor • Targeted Protein Degradation • AR • CD8

GBP1 as a machine learning-prioritized biomarker and therapeutic target for epstein-barr virus-induced clear cell renal cell carcinoma: multi-omics causal validation. (PubMed, Int J Surg) - "This work reveals a causal relationship between EBV infection and ccRCC pathogenesis, establishing GBP1 as a top-priority candidate molecule through a multi-level, multi-dimensional evidence framework. Drug prediction and molecular docking suggest finasteride as a potential inhibitor of GBP1, offering new strategies for the precise prevention and treatment of ccRCC."

Biomarker • Journal • Clear Cell Renal Cell Carcinoma • Epstein-Barr Virus Infections • Genito-urinary Cancer • Infectious Disease • Oncology • Solid Tumor • GBP1 • GBP5 • IFI16 • IL12RB1 • RECQL

Drug-Drug Coamorphous System of Tadalafil and Finasteride for Enhanced Pharmaceutical Performance. (PubMed, Mol Pharm) - "Physical stability of the developed coamorphous system evaluated under accelerated as well as long-term stability conditions indicated reasonable stability for potential drug product usage. Considering its industrial applicability due to obvious benefits, viz., single solid phase, improved solubility, dissolution, and better pharmacokinetic parameters leading to higher bioavailability, the developed coamorphous system could prove to be a better therapeutic alternative over the marketed physical mixture."

Journal • Benign Prostatic Hyperplasia

Simultaneous Target-Mediated Drug Disposition-Pharmacodynamic (TMDD-PD) Modeling of Finasteride and Dutasteride: Impact of Target Binding and Turnover on Non-linear Pharmacokinetics. (PubMed, AAPS J) - "Our results further suggest that the distinct PD profiles of finasteride and dutasteride are attributable to their differing inhibition characteristics against 5αR subtypes (selectivity and affinity). These findings extend our previous work and further support the utility of TMDD-PD modeling for optimizing clinical dose and improving therapeutic outcomes for small-molecule drugs exhibiting TMDD with time-dependent target inhibition."

Journal • PK/PD data

BPH Management: New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia (clinicaltrials.gov) - P2 | N=242 | Recruiting | Sponsor: Beth Israel Deaconess Medical Center | Not yet recruiting ➔ Recruiting

Biomarker • Enrollment open • Monotherapy • Benign Prostatic Hyperplasia

Kaempferol stimulates dermal papilla cells and upregulates Wnt/β-catenin signaling pathway for androgenetic alopecia treatment. (PubMed, J Nutr Biochem) - "In vivo, oral Kae administration substantially promoted hair regeneration in an AGA mouse model, with efficacy on par with oral finasteride. In conclusion, this study presents robust evidence that Kae effectively stimulates hair growth by bolstering DPCs function and counteracting DHT-induced damage, thus holding promising therapeutic potential for AGA sufferers."

Journal • Alopecia • Immunology • CCND1

Large-scale integration of omics and electronic health records to identify potential risk protein biomarkers and therapeutic drugs for cancer prevention. (PubMed, Am J Hum Genet) - "Analyzing >3.5 million electronic health records, we conducted analyses of emulated trials for 11 drugs across 290 comparisons and identified three drugs significantly associated with reduced colorectal cancer risk: caffeine vs. paroxetine (hazard ratio [HR], 0.51; 95% confidence interval [CI], 0.41-0.64), haloperidol vs. prochlorperazine (HR, 0.47; 95% CI, 0.33-0.68), and trazodone hydrochloride vs. paroxetine (HR, 0.49; 95% CI, 0.38-0.63). Conversely, caffeine was associated with increased cancer risk in comparison with finasteride (colorectal cancer) and fluoxetine (breast cancer). Meta-analysis identified six drugs significantly associated with cancer risk, including acetazolamide, which was associated with reduced colorectal cancer risk (HR, 0.79; 95% CI, 0.72-0.87). This study identifies previously unreported protein biomarkers and candidate drug targets across six major cancer types and highlights several approved drugs with potential chemopreventive effects."

Biomarker • Journal • Breast Cancer • Colorectal Cancer • Genito-urinary Cancer • Oncology • Pancreatic Cancer • Prostate Cancer • Solid Tumor

Finasteride Use Does Not Lead to Depression or Suicide: Insights From a Large-Scale Cohort Study and Mendelian Randomization Analysis. (PubMed, J Cosmet Dermatol) - "The existing evidence does not support the relevance between systemic use of finasteride and increased risk of depression or suicide."

Journal • Alopecia • CNS Disorders • Depression • Immunology • Mood Disorders • Psychiatry

No serum estradiol changes with 5-alpha reductase inhibitors for late alopecia in cancer survivors: a retrospective cohort study. (PubMed, J Am Acad Dermatol) - No abstract available

Journal • Retrospective data • Alopecia • Breast Cancer • Endometrial Cancer • Immunology • Oncology • Solid Tumor

Comparing the therapeutic efficacy of oral minoxidil and oral finasteride in androgenic alopecia in males (ANZCTR) - P2/3 | N=62 | Recruiting | Sponsor: Pakistan naval ship Shifa hospital, Karachi

New P2/3 trial • Alopecia • Dermatology • Immunology

Terminalia chebula Retz. Fruit Extract Promotes Murine Hair Growth by Suppressing 5α-Reductase and Accelerating the Degradation of Dihydrotestosterone. (PubMed, Biomedicines) - "Although the FDA-approved drugs finasteride and minoxidil show certain efficacy, they are also associated with severe side effects. Finally, in ex vivo organ cultures, TCFE suppressed hair follicle cell apoptosis, promoted proliferation, and thereby stimulated hair growth. These findings suggest that TCFE is a promising natural treatment for AGA, likely acting through multiple mechanisms, including Wnt pathway activation, 5α-reductase inhibition, and enhanced DHT degradation."

Journal • Preclinical • Alopecia • Immunology • AKR1C1 • AKR1C3 • TGFB1

Comparative Effectiveness and Safety of Finasteride and Dutasteride in the Treatment of Benign Prostatic Hyperplasia: A Real-World Retrospective Study. (PubMed, Medicina (Kaunas)) - "Dutasteride demonstrated superior reductions in prostate volume and PSA, while both agents had comparable effects on sexual and renal function. These findings provide real-world evidence supporting the individualization of 5-ARI therapy according to patient-specific clinical characteristics."

Clinical • HEOR • Journal • Real-world evidence • Retrospective data • Benign Prostatic Hyperplasia

Cyproterone acetate for hirsutism. (PubMed, Cochrane Database Syst Rev) - "There were some differences in clinical outcome between CPA and spironolactone, CPA and flutamide, and CPA and finasteride. There were no clinical differences between CPA and the other medical therapies, possibly because of small study size, lack of standardised assessment and objective determinants of improvement in many studies. There are insufficient data presented to compare the adverse effects of all the treatment options. Larger, carefully designed studies are needed to compare efficacy and safety profiles between the therapeutic options available."

Clinical • Journal • Review • Gynecology

Uncovering Novel Biomarkers and Drug Targets for Androgenetic Alopecia via Metabolite Regulation and Multi-Tissue Validation. (PubMed, Free Radic Biol Med) - "Our integrative multi-omics analysis identified 10 potential therapeutic targets and biomarkers for AGA. SOD1 and KL stand out as strong candidates, offering promising directions for future AGA therapies."

Biomarker • Journal • Alopecia • Immunology • BRAF • CD73 • LAMC1 • NT5E • PRLR

Prostate cancer evolution after COVID-19-related prostatitis in a TMPRSS2-altered patient: a case report and review of the molecular interface between SARS-CoV-2 and prostate oncogenesis. (PubMed, Front Oncol) - "Although symptoms improved with antibiotics, LUTS persisted and were managed with finasteride and doxazosin. This is the first documented case suggesting a potential link between COVID-19-related prostatitis and subsequent prostate cancer in a TMPRSS2::ERG-altered patient without hereditary predisposition. Although causality cannot be established, the findings highlight a hypothesis-generating interface between viral infection, inflammation, and oncogenesis that warrants further study."

Journal • Breast Cancer • Genito-urinary Cancer • Infectious Disease • Novel Coronavirus Disease • Oncology • Prostate Cancer • Respiratory Diseases • Solid Tumor • ERG • PTEN • TMPRSS2

The endoscopic surgical monitoring system-guided impact factors exploring of blood loss and fluid absorption during plasmakinetic TURP: a prospective study in high-risk BPH patients. (PubMed, BMC Urol) - "Prostate volume, operation time, resected tissue weight, venous sinus opening, and present smoking (10-20cigs/d, > 20cigs/d) increase the risk of blood loss and fluid absorption during PK-TURP in high-risk patients. Preoperative finasteride treatment (7days-3months, >3months) and surgeon's experience (50-250 procedures, 250-500 procedures, > 500 procedures) reduce these risks, while surgical capsule perforation significantly increases fluid absorption risk. The ESMS represents an innovative tool for real-time blood loss and fluid absorption monitoring, enabling precision identification of impact factors and enhancing perioperative decision-making."

Journal • Benign Prostatic Hyperplasia

Identification of Metabolites for the Novel 5α-Reductase Inhibitor Epristeride In Vitro and Its Potential Impact on Doping Testing. (PubMed, Drug Test Anal) - "Given that other 5α-reductase inhibitors, such as finasteride and dutasteride, are already monitored for their potential impact on doping control, comprehensive metabolic studies of epristeride are crucial for antidoping. Notably, Phase I metabolites (M1 and M2) showed significant binding potential with these targets, whereas the Phase II metabolite (M3) exhibited lower binding stability. These findings provide a detailed understanding of epristeride's metabolic pathways and its potential biological impacts, offering valuable insights for monitoring its presence as a confounding factor in doping control."

Journal • Preclinical • Benign Prostatic Hyperplasia • CYP17A1 • CYP19A1 • CYP3A4 • ER • STAT3

Cutting Costs, Not Care: New Models for Affordable Men's Health Medications. (PubMed, Urology) - "CPDC provides significant cost savings on men's health medications compared to Medicare and GoodRx."

Journal • Benign Prostatic Hyperplasia • Erectile Dysfunction • Infertility • Sexual Disorders

Lacticaseibacillus Paracasei CCFM1350 Demonstrates Potentials in Hair Growth and Treating Alopecia in Mice. (PubMed, Probiotics Antimicrob Proteins) - "Additionally, significant alterations in the gut microbiota were observed in the CCFM1350-treated group, including changes in the abundance of Verrucomicrobia and Bacteroidetes at the phylum level and Akkermansia at the genus level. These findings suggest that L. paracasei CCFM1350 could serve as a viable probiotic treatment for alopecia, providing a natural alternative to conventional drugs like Finasteride."

Journal • Preclinical • Alopecia • Immunology

Acute Granulomatous Interstitial Nephritis Post-COVID-19 Vaccination (KIDNEY WEEK 2025) - "In this case, we have identifed a patient with acute granulomatous interstitial nephritis likely associated with Moderna Covid-19 vaccine...Differentials: sarcoidosis ( chest CT neg),TB, fungal infection (culture neg) , pauci-immune glomerulonephrritis and drug (finasteride) induced reaction was considered unlikely...He responded again to prednisone and was switched to and maintained on cellcept.Althought the course is somewhat atypical, association with Moderna vaccination is more likely than other causes...Diffuse acute granulomas intersitial nephritis H&E stain. 200x"

Alopecia • Dyslipidemia • Erectile Dysfunction • Immunology • Infectious Disease • Metabolic Disorders • Nephrology • Novel Coronavirus Disease • Renal Disease • Sarcoidosis

A Randomized, Controlled, Single-Center Study of Short-Term Androgen Deprivation Therapy (ADT) Followed by Finasteride in Elderly Patients with High-Risk Benign Prostatic Hyperplasia (ChiCTR) - P=N/A | N=40 | Not yet recruiting | Sponsor: Shanghai General Hospital; Shanghai General Hospital

New trial • Benign Prostatic Hyperplasia

The therapeutic effect of i-PRF on androgenic alopecia and the expression of β-Catenin, CD34 and Ki67 in scalp tissue (ChiCTR) - P=N/A | N=100 | Not yet recruiting | Sponsor: The Second Affiliated Hospital of Guangxi Medical University; The Second Affiliated Hospital of Guangxi Medical University

New trial • Alopecia • Dermatology • Immunology

Efficacy and safety of twice- or thrice-weekly dutasteride versus daily finasteride in men with androgenetic alopecia: A randomized, investigator-blinded, active-controlled, parallel-group pilot study. (PubMed, JAAD Int) - "Twice-weekly and thrice-weekly regimens of dutasteride increased hair growth and were well-tolerated. Although thrice-weekly dutasteride was significantly superior to twice-weekly dutasteride, in terms of hair density and diameter, thrice-weekly dutasteride did not significantly increase hair count over finasteride 1 mg daily."

Journal • Alopecia • Immunology

Advanced medical treatments for hair loss. (PubMed, Cell Transplant) - "Normally, physicians treat hair loss using medications such as minoxidil and finasteride. Furthermore, gene therapy and tissue engineering have also been developed as treatments for hair loss. In this review, we discuss (i) the basic knowledge and molecular signaling relevant to hair regeneration and (ii) advanced technology medical treatments for hair loss (stem cells, HFCs, growth factor, EVs, gene therapy, and tissue engineers)."

Journal • Review • Aesthetic Medicine • Alopecia • Gene Therapies • Transplantation

5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy (clinicaltrials.gov) - P=N/A | N=120 | Recruiting | Sponsor: Beth Israel Deaconess Medical Center | Trial completion date: Nov 2025 ➔ Nov 2026 | Trial primary completion date: Jun 2025 ➔ Jun 2026

Trial completion date • Trial primary completion date • Benign Prostatic Hyperplasia • Pain • Urology